<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857582</url>
  </required_header>
  <id_info>
    <org_study_id>ACHIM 1</org_study_id>
    <nct_id>NCT02857582</nct_id>
  </id_info>
  <brief_title>Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile</brief_title>
  <official_title>Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Hellström</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Gävleborg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have received antibiotics and thereafter developed diarrhea are investigated for
      presence of Clostridium difficile toxin. Primary treatment is given with oral
      metronidazole/vancomycin. In case of relapse, secondary treatment is given with either
      cultured gut microbiota rectally or oral vancomycin in sequence. In those cases where
      secondary treatment with vancomycin fails cultured gut microbiota is given as final
      treatment. As an extension treatment, all failures were treated with cluttered gut microbiota
      through the upper route. In both cases As an alternative cultured gut microbiota may be given
      via the duodenal route. Follow-up is carried out after 7, 30 and 90 days with interview and
      stool collection for analysis of Clostridium difficile.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of stool consistency</measure>
    <time_frame>90 days</time_frame>
    <description>Normalization according to Bristol stool scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of stool frequency</measure>
    <time_frame>90 days</time_frame>
    <description>Normalization to less than three bowel movements per day</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Clostridium Difficile</condition>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Secondary treatment for relapse of Clostridium difficile infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cultured human intestinal microbiota1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cultured intestinal microbiota is experimental treatment for relapse of Clostridium difficile infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cultured human intestinal microbiota2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cultured intestinal microbiota is thirdly experimental treatment for second relapse of Clostridium difficile infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cultured human intestinal microbiota</intervention_name>
    <description>Secondary treatment for C diff in replacement for regular vancomycin.</description>
    <arm_group_label>Cultured human intestinal microbiota1</arm_group_label>
    <arm_group_label>Cultured human intestinal microbiota2</arm_group_label>
    <other_name>Anaerobic cultured human intestinal microbiota (ACHIM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Active comparator to treatment with ACHIM</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Primary treatment for C diff in all treatment arms</description>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_label>Cultured human intestinal microbiota1</arm_group_label>
    <arm_group_label>Cultured human intestinal microbiota2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Antibiotic-induced diarrhea

          -  Positive fecal analysis for Clostridium difficile toxin

        Exclusion Criteria:

          -  Antibiotic treatment

          -  Probiotic treatment

          -  Intestinal infection other than Clostridium difficile

          -  Inflammatory bowel disease (Ulcerative colitis, Crohn's disease

          -  Immunodeficiency (drug- och disease-related)

          -  Pregnancy

          -  Unable to accept endoscopic procedures

          -  Unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hellström M Per, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farzad Azimi, MD</last_name>
    <phone>+46 26154000</phone>
    <email>Farzad.Azimi@lg.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Norin, PhD</last_name>
    <phone>+46 852486726</phone>
    <email>Elisabeth.Norin@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <state>Gävleborg</state>
        <zip>801 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Norin, PhD</last_name>
      <phone>+468 52486726</phone>
      <email>Elisabeth.Norin@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Farzad Azimi, MD</last_name>
      <phone>46 26154000</phone>
      <email>Farzad.Azimi@lg.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.</citation>
    <PMID>23323867</PMID>
  </results_reference>
  <results_reference>
    <citation>Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011 Dec;9(12):1044-9. doi: 10.1016/j.cgh.2011.08.014. Epub 2011 Aug 24. Review.</citation>
    <PMID>21871249</PMID>
  </results_reference>
  <results_reference>
    <citation>Husebye E, Hellström PM, Sundler F, Chen J, Midtvedt T. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol. 2001 Mar;280(3):G368-80.</citation>
    <PMID>11171619</PMID>
  </results_reference>
  <results_reference>
    <citation>Gustafsson A, Berstad A, Lund-Tønnesen S, Midtvedt T, Norin E. The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea. Scand J Gastroenterol. 1999 Jun;34(6):580-6.</citation>
    <PMID>10440607</PMID>
  </results_reference>
  <results_reference>
    <citation>Gustafsson A, Lund-Tønnesen S, Berstad A, Midtvedt T, Norin E. Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol. 1998 Jul;33(7):721-7.</citation>
    <PMID>9712236</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>Per Hellström</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Antibiotic-induced diarrhea</keyword>
  <keyword>Clostridium-difficile toxin</keyword>
  <keyword>Pseudomembranous colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

